MEDP
Medpace Holdings Inc.
Company Overview
| Mkt Cap | $15.47B | Price | $419.75 |
| Volume | 363.54K | Change | +0.59% |
| P/E Ratio | 34.3 | Open | $419.52 |
| Revenue | $2.5B | Prev Close | $417.29 |
| Net Income | $451.1M | 52W Range | $284.48 - $628.92 |
| Div Yield | N/A | Target | $457.45 |
| Overall | 47 | Value | 50 |
| Quality | 71 | Technical | 20 |
No chart data available
About Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest News
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medpace Holdings (MEDP), Siegfried Holding AG (OtherSGFEF) and Edwards Lifesciences (EW)
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP) and Acadia Healthcare (ACHC)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV), Medpace Holdings (MEDP) and Cytokinetics (CYTK)
Medpace Announces Strong Q1 Results Amid Leadership Transition
Medpace Holdings Faces Investor Lawsuit Over Alleged Misleading Book-to-Bill Guidance
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MEDP | $419.75 | +0.6% | 363.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |